Controversy and debate on dengue vaccine series-paper 2: response to review of a licensed dengue vaccine: inappropriate subgroup analyses and selective reporting may cause harm in mass vaccination programs
J Clin Epidemiol
.
2018 Mar:95:140-141.
doi: 10.1016/j.jclinepi.2017.12.024.
Epub 2018 Jan 3.
Authors
Sri Rezeki S Hadinegoro
1
,
Jose Luis Arredondo-García
2
,
Maria Rosario Capeding
3
,
Sophie Pallardy
4
,
Fernando Noriega
5
,
Alain Bouckenooghe
6
Affiliations
1
Cipto Mangunkusumo Hospital, University of Indonesia, Jakarta, Indonesia. Electronic address:
[email protected]
.
2
Instituto Nacional de Pediatria, Unidad de Apoyo a la Investigación Clínic, Mexico City, Mexico.
3
Research Institute for Tropical Medicine, Medical Department, Alabang, Muntinlupa, Philippines.
4
Sanofi Pasteur, Biostatistics, Marcy l'Etoile, France.
5
Sanofi Pasteur, Global Clinical Science, Swiftwater, PA, USA.
6
Sanofi Pasteur, Global Clinical Science, Singapore, Singapore.
PMID:
29306062
DOI:
10.1016/j.jclinepi.2017.12.024
No abstract available
Publication types
Comment
MeSH terms
Dengue Vaccines*
Dengue*
Humans
Mass Vaccination
Substances
Dengue Vaccines